Rallybio (NASDAQ:RLYB) Releases Earnings Results, Misses Estimates By $0.26 EPS

Rallybio (NASDAQ:RLYB) released its quarterly earnings results on Wednesday. The company reported ($1.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.26), FiscalAI reports. The business had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.23 million. Rallybio had a negative net margin of 1,046.39% and a negative return on equity of 56.93%.

Rallybio Trading Up 2.3%

RLYB traded up $0.32 during trading on Wednesday, hitting $14.35. The stock had a trading volume of 150,607 shares, compared to its average volume of 237,998. The firm has a market cap of $75.91 million, a PE ratio of -5.61 and a beta of -1.10. Rallybio has a 12 month low of $2.16 and a 12 month high of $15.31. The company has a 50 day simple moving average of $9.63 and a 200-day simple moving average of $6.86.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Wall Street Zen upgraded Rallybio to a “hold” rating in a report on Saturday, March 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Rallybio in a report on Friday. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Insider Transactions at Rallybio

In other Rallybio news, major shareholder Adar1 Capital Management, Llc purchased 35,101 shares of the stock in a transaction dated Tuesday, May 5th. The shares were bought at an average cost of $14.00 per share, with a total value of $491,414.00. Following the completion of the transaction, the insider owned 779,784 shares in the company, valued at $10,916,976. This trade represents a 4.71% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.30% of the stock is owned by company insiders.

Institutional Trading of Rallybio

Several hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC grew its holdings in Rallybio by 16.9% in the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after buying an additional 120,892 shares during the last quarter. Citadel Advisors LLC lifted its holdings in shares of Rallybio by 576.1% during the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after buying an additional 373,821 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Rallybio by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after acquiring an additional 2,996 shares during the period. Susquehanna International Group LLP boosted its position in shares of Rallybio by 485.9% in the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after acquiring an additional 113,031 shares during the period. Finally, XTX Topco Ltd grew its stake in shares of Rallybio by 64.6% in the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after acquiring an additional 38,205 shares during the last quarter. Institutional investors own 90.34% of the company’s stock.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.